Markets

Market

News Details

(28/04/2026 21:30)

Piramal Pharma Q4 net profit down 5.64% at Rs 261.63 cr

The company reported standalone net profit of Rs 261.63 crore for the quarter ended March 31, 2026 as compared to Rs 277.27 crore in the same period last year, registering a year-on-year decline of 5.64 per cent.

Net revenue of the company declined moderately by 11.88 per cent at Rs 1,489.06 crore in January-March quarter of this fiscal as against Rs 1,689.80 crore in the corresponding period last year.

During January-March quarter, operating expenses dropped by 6.87 per cent to Rs 1,185.71 crore from Rs 1,273.22 crore in year ago period.

Other Income grew by 364.92 per cent at Rs 183.69 crore versus (Mar'25 Rs 39.51 crore).

Operating Profit slipped by 27.18 per cent to Rs 303.35 crore as against Rs 416.58 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 17.36 per cent in March quarter.

Interest declined by 36.19 per cent y-o-y to Rs 19.50 crore, while Taxation decreased by 19.37 per cent at Rs 70.22 crore (Mar'25 Rs 87.09 crore).

Prevent Unauthorized Transactions in your demat account -> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL on the same day....................issued in the interest of investors.
KYC is one-time exercise while dealing in securities markets -> Once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.